目的 探讨肾炎康复片联合布美他尼治疗慢性肾小球肾炎的临床疗效。方法 选取2020年2月—2022年2月界首市人民医院收治的87例慢性肾小球肾炎患者，按照随机数字表法将所有患者分成对照组（44例）和治疗组（43例）。对照组口服布美他尼片，初始剂量0.5～2 mg/d，必要时间隔4～5 h可重复1次，每天最大剂量为10～20 mg。治疗组在对照组治疗的基础上口服肾炎康复片，2.4 g/次，3次/d。两组均连续治疗8周。观察两组的临床疗效和头晕目眩、腰膝酸痛、面浮肢肿、食少纳呆、夜尿频多、疲倦乏力改善时间，比较两组治疗前后肾功能指标和尿常规指标的变化情况。结果 经治疗，治疗组总有效率是97.67%，显著高于对照组的81.82%（P＜0.05）。经治疗，治疗组头晕目眩、腰膝酸痛、面浮肢肿、食少纳呆、夜尿频多、疲倦乏力等临床症状改善时间均短于对照组（P＜0.05）。经治疗，两组24 h尿总蛋白（24 h Upro）、血肌酐（Scr）、尿素氮（BUN）、尿白蛋白排泄率（UAER）均较同组治疗前显著降低（P＜0.05）；且治疗后治疗组肾功能指标低于对照组（P＜0.05）。经治疗，两组患者尿液中白细胞、红细胞计数均较同组治疗前显著降低（P＜0.05），治疗后，治疗组尿液中白细胞、红细胞计数均低于对照组（P＜0.05）。结论 肾炎康复片联合布美他尼治疗慢性肾小球肾炎效果确切，可显著改善患者肾功能指标，促进相关症状改善，值得临床推广应用。

Objective To investigate the clinical efficacy of Shenyan Kangfu Tablets combined with bumetanide in treatment of chronic glomerulonephritis. Methods A total of 87 patients with chronic glomerulonephritis admitted to Jieshu People's Hospital from February 2020 to February 2022 were selected, and all patients were divided into control group (44 cases) and treatment group (43 cases) according to random number table method. Patients in the control group were po administered with Bumetanide Tablets, the initial dosage was 0.5-2 mg/d, which could be repeated 4-5 h when necessary. The maximum dosage was 10-20 mg daily. Patients in the treatment group were po administered with Shenyan Kangfu Tablets on the basis of the control group, 2.4 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy and improvement time of the clinical symptoms such as dizziness, waist and knee soreness, floating limb swelling, lack of food and lethargy, nocturnal frequent urination, and fatigue were observed in the two groups. The changes of renal function indexes and urine routine indexes before and after treatment were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 97.67%, significantly higher than that of the control group 81.82% (P < 0.05). After treatment, the improvement time of clinical symptoms such as dizziness, waist and knee soreness, floating limb swelling, lack of appetite, nocturnal frequent urination, and fatigue in treatment group was shorter than that in control group (P < 0.05). After treatment, 24 h Upro, Scr, BUN, and UAER in two groups were significantly decreased compared with before treatment (P < 0.05). The renal function index of the treatment group was lower than that of the control group (P < 0.05). After treatment, WBC and RBC counts in urine in two groups were significantly lower than before treatment (P < 0.05), and WBC and RBC counts in urine in treatment group were lower than control group after treatment (P < 0.05). Conclusion Shenyan Kangfu Tablets combined with bumetanide has exact effect in treatment of chronic glomerulonephritis, and can significantly improve patients' renal function index and promote the improvement of related symptoms, which is worthy of clinical application.

R983

安徽省卫生厅中医药科研计划项目(2014zy93)